{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:28:48Z","timestamp":1788834528389,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Some patients with psoriasis experience relapses shortly after discontinuation of biologics. However, there is a lack of risk prediction tools to identify those at high risk of relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop and validate a risk prediction model for psoriasis relapse after biologics discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publications from PubMed, EMBASE, Medline, and the Cochrane Library were systematically searched and meta-analyses were conducted to identify risk factors for psoriasis relapse after biologics discontinuation. Statistically significant risk factors were identified and used to create a risk assessment model weighted by the impact of each factor. The model was externally validated using a cohort of 416 Chinese psoriasis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eight studies (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20092066) were included in the meta-analysis. Body mass index (BMI), smoking, disease duration, comorbid psoriatic arthritis (PsA), remission speed and extent during treatment, history of biologic therapy, and therapy duration were identified as correlates of relapse in the meta-analysis and were incorporated into the prediction model. The median age of the 416 patients in the validation cohort was 41.5 (IQR 32, 53) years, with 63% male, and a baseline PASI score of 15.4 (IQR 10.5, 21). It was verified that the area under the curve (AUC) of the prediction model was 0.796 (95% CI, 0.753\u20130.839), with an optimal cut-off value of 11.25 points, sensitivity of 65.1%, and specificity of 82.2%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Multivariate models using available clinical parameters can predict relapse risk in psoriasis patients after biologics discontinuation. Early individual identification of patients at risk of relapse, and screening of candidate cohorts for long-term treatment or dose reduction may benefit both patients and physicians.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2024.1488096","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T23:23:01Z","timestamp":1732576981000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Development and external validation of a prediction model for the risk of relapse in psoriasis after discontinuation of biologics"],"prefix":"10.3389","volume":"11","author":[{"given":"Shan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwu","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA J Am Med Assoc"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/14712598.2022.2100219","article-title":"Pathogenesis-oriented therapy of psoriasis using biologics","volume":"22","author":"Boehncke","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/bjd.19325","article-title":"Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network Meta-analysis","volume":"183","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/jdv.14387","article-title":"Early relapse of psoriasis after stopping Brodalumab: a retrospective cohort study in 77 patients","volume":"31","author":"Masson Regnault","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1001\/jamadermatol.2021.3492","article-title":"Effect of costimulatory blockade with Abatacept after Ustekinumab withdrawal in patients with moderate to severe plaque psoriasis: the pause randomized clinical trial","volume":"157","author":"Harris","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40257-022-00679-y","article-title":"Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review","volume":"23","author":"Masson Regnault","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/bjd.20963","article-title":"The biological basis of disease recurrence in psoriasis: a historical perspective and current models","volume":"186","author":"Puig","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/ijms21020625","article-title":"Immunological memory of psoriatic lesions","volume":"21","author":"Owczarczyk Saczonek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms20184347","article-title":"Risk factors for the development of psoriasis","volume":"20","author":"Kamiya","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/jdv.16964","article-title":"Time to relapse after Tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64weeks from resurface 1 trial","volume":"35","author":"Warren","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/jocd.15638","article-title":"Clinical course of psoriasis patients that discontinued biologics during the Covid-19 pandemic","volume":"22","author":"Topalo\u011flu Demir","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/ejcts\/ezy180","article-title":"Statistical primer: developing and validating a risk prediction model","volume":"54","author":"Grant","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/aln.0000000000003871","article-title":"Statistical development and validation of clinical prediction models","volume":"135","author":"Staffa","year":"2021","journal-title":"Anesthesiology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and Meta-analysis protocols (Prisma-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"ref16","year":""},{"key":"ref17","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (Tripod): the Tripod statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1128069","DOI":"10.3389\/fpubh.2023.1128069","article-title":"Development and validation of a risk prediction model for early diabetic peripheral neuropathy based on a systematic review and Meta-analysis","volume":"11","author":"Liu","year":"2023","journal-title":"Front Public Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jaad.2019.01.035","article-title":"Predictors of time to relapse following Ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an 8-year multicenter study","volume":"88","author":"Chiu","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.23736\/S0392-0488.18.06156-4","article-title":"A multicenter retrospective case-control study on suspension of Tnf-inhibitors and outcomes in psoriatic patients (stop study)","volume":"154","author":"Stinco","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2165\/11537470-000000000-00000","article-title":"Treating psoriasis with Etanercept in Italian clinical practice: prescribing practices and duration of remission following discontinuation","volume":"30","author":"Arcese","year":"2010","journal-title":"Clin Drug Investig"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.det.2018.07.004","article-title":"Biologics and psoriasis: the beat Goes on","volume":"37","author":"Kim","year":"2019","journal-title":"Dermatol Clin"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/jdv.12636","article-title":"Predictors of Adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the bio-capture registry","volume":"29","author":"van den Reek","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2147\/CCID.S387759","article-title":"Drug survival outcomes associated with the real-world use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the treatment of plaque psoriasis in China: a 52-week single-center retrospective study","volume":"15","author":"Li","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1111\/dth.15052","article-title":"Real-world evidence on time to relapse of plaque psoriasis after discontinuation of biologic treatment in Poland","volume":"34","author":"Owczarek","year":"2021","journal-title":"Dermatol Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum Il-23-regulated Il-17 and Il-22 in psoriasis: voyage 2 study","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1111\/jdv.16809","article-title":"Maintenance of response following discontinuation of Guselkumab and Secukinumab in Spanish patients who participated in the eclipse study","volume":"35","author":"Rivera","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","article-title":"Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis","volume":"160","author":"Hjort","year":"2024","journal-title":"JAMA Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s13555-019-0310-5","article-title":"Remission duration and long-term outcomes in patients with moderate-to-severe psoriasis treated by biologics or Tofacitinib in controlled clinical trials: a 15-year single-center experience","volume":"9","author":"Huang","year":"2019","journal-title":"Dermatol Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e049822","DOI":"10.1136\/bmjopen-2021-049822","article-title":"Il-23 blockade with Guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (guide)","volume":"11","author":"Eyerich","year":"2021","journal-title":"BMJ Open"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2355261","DOI":"10.1080\/09546634.2024.2355261","article-title":"Adjunctive Chinese medicine therapy reduces relapse of psoriasis vulgaris after discontinuation of biologics: a prospective registry-based cohort study","volume":"35","author":"Huang","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamadermatol.2019.4897","article-title":"Comparison of tightly controlled dose reduction of biologics with usual Care for Patients with psoriasis: a randomized clinical trial","volume":"156","author":"Atalay","year":"2020","journal-title":"JAMA Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1369805","DOI":"10.3389\/fphar.2024.1369805","article-title":"Dose reduction of biologics in patients with plaque psoriasis: a review","volume":"15","author":"van Riel","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/ftd.0000000000000420","article-title":"Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study","volume":"39","author":"van Bezooijen","year":"2017","journal-title":"Ther Drug Monit"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/ced\/llad329","article-title":"Investigation of plaque psoriasis relapse after Secukinumab withdrawal in patients from two phase 3 studies","volume":"49","author":"Lebwohl","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jdv.15292","article-title":"Long-term efficacy and safety results from an open-label phase iii study (uncover-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of Ixekizumab","volume":"33","author":"Umezawa","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1488096\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T23:23:06Z","timestamp":1732576986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1488096\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":36,"alternative-id":["10.3389\/fmed.2024.1488096"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1488096","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"article-number":"1488096"}}